This aligns with other recently published data showing how low levels of IGFBP-3 increased the risk of cardiovascular disease and mortality (18) and how low IGF-I/IGFBP-3 ratios increased the risk of metabolic syndrome and insulin resistance (68). This evidence concerns the gene IGFBP3 and metabolic syndrome.